A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

Phase Ii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress

Annals of Oncology ◽

10.1093/annonc/mdy151.181 ◽

2018 ◽

Vol 29 ◽

pp. v51

Author(s):

S. Qin ◽

R. Finn ◽

M. Kudo ◽

T. Meyer ◽

A. Vogel ◽

...

Keyword(s):

Multicenter Study ◽

Study Trial ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7591 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7591-7591 ◽

Cited By ~ 2

Author(s):

J. Liang ◽

M. Ahn ◽

J. Kang ◽

Q. Xiu ◽

Y. Chen ◽

...

Keyword(s):

Phase Ii ◽

Advanced Nsclc ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Never Smoker ◽

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps3110 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3110-TPS3110 ◽

Cited By ~ 8

Author(s):

Shukui Qin ◽

Richard S. Finn ◽

Masatoshi Kudo ◽

Tim Meyer ◽

Arndt Vogel ◽

...

Keyword(s):

Multicenter Study ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.4013 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 4013-4013 ◽

Cited By ~ 8

Author(s):

David Malka ◽

Florence Castan ◽

Eric Francois ◽

Olivier Bouche ◽

Jaafar Bennouna ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Gastroesophageal Adenocarcinoma ◽

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial

Annals of Translational Medicine ◽

10.21037/atm-20-2990 ◽

2020 ◽

Vol 8 (17) ◽

pp. 1047-1047

Author(s):

Zhenyu Hou ◽

Keyun Zhu ◽

Xuejiao Yang ◽

Ping Chen ◽

Wei Zhang ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

935P An exploratory subgroup analysis of a phase II/III trial of donafenib versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2021.08.155 ◽

2021 ◽

Vol 32 ◽

pp. S820

Author(s):

F. Bi ◽

S. Qin ◽

S. Gu ◽

Y. Bai ◽

Z. Chen ◽

...

Keyword(s):

Phase Ii ◽

Subgroup Analysis ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

Faculty Opinions recommendation of FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717997102.793478384 ◽

2013 ◽

Author(s):

Sabine Tejpar ◽

Loredana Vecchione

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00110-2 ◽

2021 ◽

Author(s):

Arndt Vogel ◽

Shukui Qin ◽

Masatoshi Kudo ◽

Yun Su ◽

Stacie Hudgens ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Unresectable Hepatocellular Carcinoma ◽

Carcinoma Patient ◽

Patient Reported ◽

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Annals of Oncology ◽

10.1093/annonc/mdt116 ◽

2013 ◽

Vol 24 (7) ◽

pp. 1769-1777 ◽

Cited By ~ 27

Author(s):

T. Brodowicz ◽

T.E. Ciuleanu ◽

D. Radosavljevic ◽

E. Shacham-Shmueli ◽

D. Vrbanec ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽